A medicine for treating rheumatoid arthritis and uses thereof

A rheumatoid and arthritis technology, applied in the field of drugs for the treatment of rheumatoid arthritis, can solve the problems of increased production of matrix metalloproteinases and destruction of articular cartilage

Inactive Publication Date: 2019-01-15
LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

IL-6 and IL-1 work together to increase the production of matrix metalloproteinases, leading to the destruction of articular cartilage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A medicine for treating rheumatoid arthritis and uses thereof
  • A medicine for treating rheumatoid arthritis and uses thereof
  • A medicine for treating rheumatoid arthritis and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

experiment example

[0019] The CIA model of DBA / 1 mice was established. DBA / 1 female mice for 6-8 weeks, after adaptive feeding for 1 week, use bovine type II collagen (2mg / mL) and complete Freund's adjuvant (BCG concentration is 4mg / ml), after complete emulsification, inject 100μL of the tail subcutaneously (containing 100μg bovine type II collagen), and 21 days later, the second immunization was carried out, using bovine type II collagen (2mg / mL) and incomplete Freund's adjuvant, after complete emulsification, 100μL (containing 100μg bovine type II collagen) was subcutaneously injected into the tail . After the second immunization of DBA / 1 mice on the first day (D20), the model mice were randomly divided into groups, namely, an osthole group and a model group, with more than 10 mice in each group. In the osthole group, osthole was dissolved in 0.5% sodium carboxymethylcellulose (CMC-Na) to prepare a suspension, and in the model group, 0.5% CMC-Na was used. The dosage of osthole is 50mg / kg. O...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicine for treating rheumatoid arthritis, wherein the effective component is osthole, and the effective concentration is 1-100 [mu]M. Osthole is mixed with pharmaceutically acceptable pharmaceutical adjuvants to form powders, ointments, powders, injections, aqueous solutions, enteric-coated sustained-release preparations or injections. As prove by animal experiments, osthole can reduce joint injury and inflammatory infiltration area of collagen-induced rheumatoid arthritis mice, reduce bone mas defect, alleviate ankle arthritis injury, and improve rheumatoid arthritis symptoms. The invention also discloses the use of osthole in preparing medicine or health product for preventing and treating rheumatoid arthritis.

Description

technical field [0001] The invention relates to a medicine for treating rheumatoid arthritis, and proposes the application of the medicine in preparing various forms of medicines or health food for preventing and treating rheumatoid arthritis. Background technique [0002] The prior art discloses that rheumatoid arthritis (Rheumatoid Arthritis, RA) is a chronic, systemic, progressive, autoimmune disease characterized by widespread persistent synovitis and symmetrical, destructive joint Lesions are characteristic. The treatment of RA is very difficult, so far, there is still a lack of safe and effective drugs. Modern medicine is mainly about anti-inflammation and alleviating sequelae. Drugs such as TNFα inhibitors Etanercept, Infliximab and Adalimumab can reduce some objective symptom indicators such as swelling and tender joint counts to 50% in some RA patients, but many patients still have problems in initial treatment. Its non-response, or the failure of the second treat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/37A61P19/02A61P29/00
Inventor 梁倩倩王拥军徐浩施杞贾庆运王腾腾王琼王晓赟陈涛陈锦漫刘洋王怡茹齐晓凤许崇卿刘利李强赵永见
Owner LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap